EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Intravenous Paricalcitol Versus Calcitriol for Secondary Hyperparathyroidism in Maintenance Hemodialysis: A Six-Month Single-Center Retrospective Cohort Study

Erman Özdemir iD, Erdoğan Özdemir iD, Pınar Özdemir iD

Journal of Clinical Medicine · 13.07.2026 · 15 (14) · 5483

DOI: 10.3390/jcm15145483 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of Clinical Medicine, online erschienen am 13.07.2026. Verfasst von Erman Özdemir und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Pendik State Hospital, 34890 Istanbul, Turkey. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Secondary hyperparathyroidism is a frequent component of chronic kidney disease-mineral and bone disorder in maintenance hemodialysis. Calcitriol and paricalcitol are used to suppress intact parathyroid hormone (iPTH), but the comparative advantage of paricalcitol in routine practice remains uncertain. This study compared 6-month biochemical PTH control in patients treated with intravenous calcitriol or intravenous paricalcitol.

Methods

In this single-center retrospective cohort study, 312 adult hemodialysis patient files from 2023 to 2025 were screened. Patients who did not receive either intravenous study agent, switched between agents, or did not complete 6 months of treatment with the same agent were excluded. The final cohort included 185 patients, 100 treated with calcitriol and 85 with paricalcitol. The primary endpoint was target iPTH at 6 months, defined as 150–600 pg/mL.

Results

Mean age was 58.9 ± 13.6 years, and 106 patients were male. Baseline iPTH was similar in the calcitriol and paricalcitol groups (684 ± 268 vs. 712 ± 291 pg/mL; p = 0.498). At 6 months, iPTH decreased significantly in both groups, with no significant between-group difference in follow-up iPTH (421 ± 214 vs. 398 ± 205 pg/mL; p = 0.456), percentage iPTH reduction (−36.8 ± 22.4% vs. −39.5 ± 24.1%; p = 0.431), or target iPTH achievement (62.0% vs. 60.0%; p = 0.781). Hypercalcemia and hyperphosphatemia rates were also similar. In multivariable analysis, treatment type was not independently associated with target iPTH achievement, whereas higher baseline iPTH and phosphorus were associated with lower odds of achieving target iPTH.

Conclusions

Intravenous paricalcitol was not associated with superior 6-month PTH control compared with intravenous calcitriol in this real-world maintenance hemodialysis cohort. The findings indicate no demonstrated superiority of paricalcitol in this cohort and should not be interpreted as proof of pharmacological equivalence.

Schlagwörter

Stichwörter der Autor:innen

calcitriolhemodialysisparicalcitolsecondary hyperparathyroidism

Autor:innen und Institutionen

  • Department of Nephrology, Pendik State Hospital, 34890 Istanbul, Turkey.
  • Department of Internal Medicine, Elazığ Fethi Sekin City Hospital, 23100 Elazığ, Turkey.
  • Department of Nephrology, Kartal Dr. Lütfi Kırdar City Hospital, 34865 Istanbul, Turkey.

ORCID-Profile: Erman Özdemir, Erdoğan Özdemir, Pınar Özdemir

Zitieren

APA

Özdemir, E., Özdemir, E., & Özdemir, P. (2026). Intravenous Paricalcitol Versus Calcitriol for Secondary Hyperparathyroidism in Maintenance Hemodialysis: A Six-Month Single-Center Retrospective Cohort Study. Journal of Clinical Medicine, 15(14), 5483. https://doi.org/10.3390/jcm15145483

Vancouver

Özdemir E, Özdemir E, Özdemir P. Intravenous Paricalcitol Versus Calcitriol for Secondary Hyperparathyroidism in Maintenance Hemodialysis: A Six-Month Single-Center Retrospective Cohort Study. Journal of Clinical Medicine. 2026;15(14):5483. doi:10.3390/jcm15145483

BibTeX
@article{zdemir2026,
  author = {Özdemir, Erman and Özdemir, Erdoğan and Özdemir, Pınar},
  title = {Intravenous Paricalcitol Versus Calcitriol for Secondary Hyperparathyroidism in Maintenance Hemodialysis: A Six-Month Single-Center Retrospective Cohort Study},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {14},
  pages = {5483},
  doi = {10.3390/jcm15145483}
}
Kostenlos starten →